Simon Harrison

Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap

Anthony P Longhitano, Monica A Slavin, Simon J Harrison, Benjamin W Teh

Journal article  |  2021  |  BLOOD REVIEWS

Relapsed haematological malignancies have a poor disease prognosis with current therapies. Bispecific antibodies (BsAbs) are becom..

The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies

Dawn Swan, David Routledge, Simon Harrison

Journal article  |  2021  |  BRITISH JOURNAL OF HAEMATOLOGY

Treatment outcomes in multiple myeloma (MM) have improved dramatically over the past 10 years. However, patients with high-risk di..

Myeloma natural killer cells are exhausted and have impaired regulation of activation

Criselle D'Souza, Simon P Keam, Han Xian Aw Yeang, Michael Neeson, Kelden Richardson, Andy K Hsu, Rachael Canfield, Natalie Bezman, Michael Robbins, Hang Quach, David S Ritchie, Simon J Harrison, Joseph A Trapani, H Miles Prince, Paul A Beavis, Phillip K Darcy, Paul J Neeson

Journal article  |  2021  |  HAEMATOLOGICA

Not available.

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

Nizar J Bahlis, Rachid Baz, Simon J Harrison, Hang Quach, Shir-Jing Ho, Annette Juul Vangsted, Torben Plesner, Philippe Moreau, Simon D Gibbs, Sheryl Coppola, Xiaoqing Yang, Abdullah Al Masud, Jeremy A Ross, Orlando Bueno, Jonathan L Kaufman

Journal article  |  2021  |  J Clin Oncol

PURPOSE: Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma..

Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement

Nada Hamad, Michelle Ananda-Rajah, Nicole Gilroy, Raina MacIntyre, David Gottlieb, David Ritchie, Simon Harrison, Glen Kennedy, Anne M Watson, Matthew Greenwood, Richard Doocey, Travis Perera, Andrew Spencer, Eric Wong, Tracey O'Brien, Peter Shaw, Rachel Conyers, Samuel Milliken, Peter Bardy, Stephen Larsen, et al.

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vacci..

KRd: the new KiD in the French myeloma induction class

Jeremy Er, Simon J Harrison

Journal article  |  2021  |  BLOOD

Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies

Chhay Lim, Priyadarshini Sinha, Simon J Harrison, Hang Quach, Monica A Slavin, Benjamin W Teh

Journal article  |  2021  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

INTRODUCTION: Treatment for multiple myeloma (MM) has continued to evolve with second generation immunomodulatory drugs (IMiDs), p..

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction

Stephen Boyle, Cameron Wellard, Elizabeth M Moore, Hilary Blacklock, Simon J Harrison, Phoebe Joy Ho, Jay Hocking, Zoe K McQuilten, Hang Quach, Ruth Spearing, Erica M Wood, Andrew Spencer, Peter Mollee

Journal article  |  2021  |  EUROPEAN JOURNAL OF HAEMATOLOGY

We read with interest the study from Rampotas et al (1) where they evaluated 158 transplant-non-eligible newly diagnosed myeloma p..

The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)

Krystal Bergin, Cameron Wellard, Elizabeth Moore, Zoe McQuilten, Hilary Blacklock, Simon J Harrison, P Joy Ho, Tracy King, Quach Hang, Peter Mollee, Patricia Walker, Erica Wood, Andrew Spencer

Journal article  |  2021  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

BACKGROUND: Real-world multiple myeloma (MM) data are scarce, with most data originating from clinical trials. The Myeloma and Rel..

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Lauren Giuffrida, Kevin Sek, Melissa A Henderson, Junyun Lai, Amanda XY Chen, Deborah Meyran, Kirsten L Todd, Emma Petley, Sherly Mardiana, Christina Molck, Gregory D Stewart, Benjamin J Solomon, Ian A Parish, Paul J Neeson, Simon J Harrison, Lev M Kats, Imran G House, Phillip K Darcy, Paul A Beavis

Journal article  |  2021  |  NATURE COMMUNICATIONS

Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the suppression of multiple immune subsets includ..